NCT ID,Brief Title,Official Title,Status,Current Phase,Start Date,Completion Date,Primary Completion Date,Conditions,Interventions,Sponsors,Locations,Study Type,Enrollment,Study Population
NCT02876419,A Long Term Follow-up Study of Patients From the REP 301 Protocol,A Long Term Follow-up Study of Patients From the REP 301 Protocol,COMPLETED,,2016-08-01T00:00:00,2019-12-01T00:00:00,2019-11-13T00:00:00,"Hepatitis B, Chronic; Hepatitis D, Chronic",,Replicor Inc.,,INTERVENTIONAL,,
NCT01449071,Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE),"A Phase1/2, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Pharmacokinetics of One 12 Week Treatment Cycle of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects With Moderate to Severe Disease",COMPLETED,"PHASE1, PHASE2",2011-10-01T00:00:00,2013-03-01T00:00:00,2013-03-01T00:00:00,Systemic Lupus Erythematosus,,UCB Pharma,,INTERVENTIONAL,,
NCT04058964,Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer,A Pilot Study to Assess the Efficacy and Safety Effects of Pembrolizumab and PEGPH20 (Pegvorhyaluronidase Alfa) in Patients With Metastatic Pancreatic Cancer,WITHDRAWN,PHASE2,2020-02-01T00:00:00,2022-10-31T00:00:00,2022-10-31T00:00:00,Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8,,M.D. Anderson Cancer Center,,INTERVENTIONAL,,
